

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 22, 2025

CD278 (ICOS)

RRID:AB_2738840

Type: Antibody

Proper Citation

(BD Biosciences Cat# 564549, RRID:AB_2738840)

Antibody Information

URL: http://antibodyregistry.org/AB_2738840

Proper Citation: (BD Biosciences Cat# 564549, RRID:AB_2738840)

Target Antigen: CD278 (ICOS)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD278 (ICOS)

Description: This monoclonal targets CD278 (ICOS)

Target Organism: human

Clone ID: DX29

Antibody ID: AB_2738840

Vendor: BD Biosciences

Catalog Number: 564549

Record Creation Time: 20231110T033523+0000

Record Last Update: 20240724T233048+0000

Ratings and Alerts

No rating or validation information has been found for CD278 (ICOS).

No alerts have been found for CD278 (ICOS).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer cell*, 42(5), 759.

Külp M, et al. (2022) Co-culture of primary human T cells with leukemia cells to measure regulatory T cell expansion. *STAR protocols*, 3(3), 101661.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Külp M, et al. (2022) The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia. *iScience*, 25(7), 104613.